English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduUC San Diego researchers suggest that prolonged exposure to a pair of antioxidant proteins may contribute to enlargement of the liver and fatty liver diseases.
Tag: Liver Disease
UCLA researchers find new method for measuring treatment of rare liver disease in children
Study examines the role of small molecule in children with a rare liver disease
Study: Two Enzymes Control Liver Damage in NASH
After identifying a molecular pathway that allows nonalcoholic steatohepatitis (NASH) to progress into liver cell death, University of California San Diego School of Medicine researchers were able to use these pathways to halt further liver damage.
Choosing Common Pain Relievers: It’s Complicated
About 29 million Americans use over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) to treat pain. Every year in the U.S., NSAID use is attributed to approximately 100,000 hospitalizations and 17,000 deaths. All of these drugs have benefits and risks, but deciding which one to use is complicated for health care providers and their patients. To assist in clinical decision-making, researchers address cardiovascular risks and beyond, which include gastrointestinal and kidney side effects of pain relievers.
Liver Fibrosis “Off Switch” Discovered in Mice
UC San Diego School of Medicine researchers identified several genetic switches, or transcription factors, that determine whether or not liver cells produce collagen — providing a new therapeutic target for liver fibrosis.
Two UC San Diego Researchers Elected AAAS Fellows
Two researchers at University of California San Diego School of Medicine—Pamela L. Mellon and Aleem Siddiqui—have been named Fellows of the American Association for the Advancement of Science (AAAS), the largest general science organization in the world and publisher of the journal Science.
Matthew R. D’Uva to Join AASLD as CEO
The American Association for the Study of Liver Diseases (AASLD) has appointed Matthew R. D’Uva, FASAE, CAE, as its new chief executive officer, effective January 21, 2020.
Innovative Machine Learning Tool Predicts Who Might Have Non-Alcoholic Steatohepatitis
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that a machine-learning tool could successfully predict the risk of having non-alcoholic steatohepatitis (NASH) among patients with co-existing diseases.
Study Shows Artificial Intelligence Can Detect Language Problems Tied to Liver Failure
Natural language processing, the technology that lets computers read, decipher, understand and make sense of human language, is the driving force behind internet search engines, email filters, digital assistants such as Amazon’s Alexa and Apple’s Siri, and language-to-language translation apps. Now, Johns Hopkins Medicine researchers say they have given this technology a new job as a clinical detective, diagnosing the early and subtle signs of language-associated cognitive impairments in patients with failing livers.
AASLD Foundation Invests $3.42 Million in Liver Disease Research and Career Development
Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest private supporter of liver disease research and training in the United States, today announced its investment of $3.42 million in Research and Career Development…